Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02989064
Recruitment Status : Active, not recruiting
First Posted : December 12, 2016
Last Update Posted : May 7, 2020
Sponsor:
Information provided by (Responsible Party):
Adaptimmune

Brief Summary:

This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Following the dose escalation phase, additional subjects will be enrolled at the target cell dose range to further characterize safety and the effects at this cell dose.

The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. When the MAGE-A10ᶜ⁷⁹⁶T cells are available, subjects will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with urothelial, melanoma or head and neck cancer.

Subjects will be seen frequently by the Study Physician after receiving their T cells for the next 6 months. After that, subjects will be seen every 3, 6, or 12 months according to the Schedule of Procedures. All subjects completing or withdrawing from the interventional portion of the study will enter a long term follow-up phase for observation of delayed adverse events and overall survival for 15 years post-infusion.


Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Head and Neck Cancer Melanoma Bladder Urothelial Carcinoma Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Actual Study Start Date : October 2016
Actual Primary Completion Date : December 18, 2019
Estimated Study Completion Date : November 2034


Arm Intervention/treatment
Experimental: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1




Primary Outcome Measures :
  1. Number of subjects with adverse events (AE), including serious adverse events (SAE). [ Time Frame: 3 years ]
    Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation; and cardiac assessments, including ECG/troponin.

  2. Evaluation of the persistence of genetically modified T cells [ Time Frame: 3 years ]
    Evaluation of the persistence of the infused T cells in the periphery.

  3. Measurement of RCL in genetically modified T cells. [ Time Frame: 3 years ]
    Evaluation of RCL in Subject PBMCs using PCR-based assay.

  4. Assessment of dose limiting toxicities to determine optimally tolerated dose range [ Time Frame: 3 years ]
    Evaluation of dose limiting toxicities will be performed using the CTCAE Version 4.0

  5. Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR). [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1

  6. Interval between the date of first T cell infusion dose and first documented evidence of CR or PR. [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of time to first response.

  7. Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause. [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of duration of response.

  8. Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause. [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of duration of stable disease.

  9. Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of progression-free survival.

  10. Interval between the date of first T cell infusion and date of death due to any cause. [ Time Frame: 3 years ]
    Evaluation of the efficacy of the treatment by assessment of overall survival.

  11. Number and % of subjects having any Long Term Follow Up Adverse Events (AEs) [ Time Frame: 15 years post last treatment (infusion) ]
    • New occurrence of any malignancy
    • New occurrence or exacerbation of a pre-existing neurologic disorder
    • New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder
    • New occurrence of a hematologic disorder
    • New occurrence of any opportunistic and/or serious infections
    • New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent.
  2. Subject has histologically confirmed diagnosis of any one of the following cancers: (A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal pelvis), (B) melanoma, or (C) squamous cell carcinoma of the head and neck.
  3. Subject is HLA-A*02:01 and/or HLA-A*02:06 positive.
  4. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
  5. Subject meets disease-specific requirements per protocol
  6. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.
  7. Subject's tumor shows positive MAGE-A10 expression
  8. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  9. Subject has a left ventricular ejection fraction ≥50%.
  10. Subject is fit for leukapheresis and has adequate venous access for the cell collection.
  11. Female subject of childbearing potential (FCBP) must have a negative urine or serum pregnancy test or male subject must be surgically sterile or agree to use a double barrier contraception method or abstain from heterosexual activity with a female of childbearing potential starting at the first dose of chemotherapy and for 4 months thereafter.
  12. Subject must have adequate organ function per protocol

Exclusion Criteria:

  1. Subject is HLA-A*02:05 in either allele, HLA-B*15:01 and/or HLA-B*46:01 positive. Subject has any A*02 null allele (designated with an "N", e.g. A*02:32N) as the sole HLA-A*02 allele.
  2. Subject has received or plans to receive excluded therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy per protocol
  3. Subject that has toxicity from previous anti-cancer therapy must have recovered to ≤ Grade 1 prior to enrollment
  4. Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
  5. Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical related toxicities.
  6. Subject has an electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing an average QTc interval ≥450 msec in males and ≥470 msec in females (≥480 msec for subjects with bundle branch block [BBB]) over 3 consecutive ECGs. Either Fridericia's or Bazett's formula may be used to correct the QT interval.
  7. Subject has symptomatic CNS metastases.
  8. Subject has a history of chronic or recurrent severe autoimmune or immune mediated disease
  9. Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening.
  10. Subject has uncontrolled intercurrent illness
  11. Subject has active infection with HIV, HBV, HCV or HTLV
  12. Subject is pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02989064


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Missouri
Washington University - School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Ohio
Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Tennessee
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States, 37203
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Canada, Ontario
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G1X6
Spain
Start Madrid-FJD, Fundación Jimѐnez Díaz
Madrid, Spain, 28040
Hospital Universitario 12 Octubre Avda. de Córdoba
Madrid, Spain, 28041
Sponsors and Collaborators
Adaptimmune
Investigators
Layout table for investigator information
Principal Investigator: David Hong, MD M.D. Anderson Cancer Center
Layout table for additonal information
Responsible Party: Adaptimmune
ClinicalTrials.gov Identifier: NCT02989064    
Other Study ID Numbers: ADP-0022-004
First Posted: December 12, 2016    Key Record Dates
Last Update Posted: May 7, 2020
Last Verified: May 2020
Keywords provided by Adaptimmune:
Cell Therapy
T Cell Therapy
SPEAR T Cell
MAGE-A10
Immuno-oncology
Metastatic
Urothelial Cancer
Previously Treated
T Cell Receptor
Inoperable
Advanced
Cancer
Bladder
Head and neck
Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Melanoma
Head and Neck Neoplasms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site